BSX / Boston Scientific (BSX) Gains From New Buyouts, Cost Woes Stay

Boston Scientific's (BSX) organic and operational revenues at its respective core business segments and geographies rise in the third quarter. more_horizontal

Boston Scientific (BSX) came out with quarterly earnings of $0.50 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to more_horizontal

Boston Scientific Corp. BSX, -1.90% posted better-than-expected third-quarter earnings early Thursday and raised its full-year guidance. The medical t more_horizontal

Medical device maker Boston Scientific topped Wall Street expectations for third-quarter profit on Thursday, helped by a resilient demand for its hear more_horizontal

Boston Scientific's quarterly results on Thursday are likely to show the benefits of a rebound in elective procedures and help ease fears that the med more_horizontal

With global staffing issues and the supply situation gradually improving, Boston Scientific's (BSX) international business is expected to have improve more_horizontal

One tool that investors can easily access for any stock is analyst ratings. These ratings point you in the direction of stocks to buy and stocks to se more_horizontal

Boston Scientific (BSX) receives the FDA's nod for an expanded indication of Wavewriter SCS Systems. more_horizontal